Trial Profile
A Phase 1 Dose Escalation Study of ARQ 197 Given Twice Daily Continuously in Adult Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Tivantinib (Primary)
- Indications Adenocarcinoma; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors ArQule
- 20 Jul 2012 Actual patient number changed from 46 to 51 as reported by ClinicalTrials.gov.
- 17 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 01 Jun 2009 Status changed from recruiting to completed. Final results in were presented at ASCO.